ITGAM and neoplasm: The total percentage of CD11b+F4/80+ tumor-associated macrophages (TAMs) did not change between the treatment groups, but the percentage of M1 (CD68+MHC-II+) macrophages was significantly increased in the ADU-S100 + anti-PD-L1 therapy cohort (Figure 3B).